mercaptoethanol has been researched along with Hematuria in 16 studies
Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.
Hematuria: Presence of blood in the urine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 9.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
| "A prospective randomised study was carried out to compare the effect of mesna (2-mercaptoethane sulphonate sodium) with that of forced diuresis in preventing cyclophosphamide induced haemorrhagic cystitis in marrow transplant recipients." | 9.05 | Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. ( Gordon, MY; Gordon-Smith, EC; Hows, JM; Mehta, A; Perez, R; Ward, L; Woods, K, 1984) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 7.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "Mesna is a sulfhydryl compound that reacts with the metabolites of cyclophosphamide that are excreted in the urine and may produce bladder wall irritation." | 5.27 | Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. ( Luce, JK; Simons, JA, 1988) |
| "European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 5.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
| "A prospective randomised study was carried out to compare the effect of mesna (2-mercaptoethane sulphonate sodium) with that of forced diuresis in preventing cyclophosphamide induced haemorrhagic cystitis in marrow transplant recipients." | 5.05 | Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. ( Gordon, MY; Gordon-Smith, EC; Hows, JM; Mehta, A; Perez, R; Ward, L; Woods, K, 1984) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 3.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "A randomized study in 20 patients with cancer was carried out to test the clinical efficacy of sodium-2-mercaptoethane sulfonate (ASTA D-7093; mesnum) as an agent to prevent urotoxic side effects (in particular, hemorrhagic cystitis) during cytostatic therapy with the oxazaphosphorines cyclophosphamide and ifosfamide." | 2.65 | Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. ( Brock, N; Burkert, H; Günther, U; Hoefer-Janker, H; Klein, HO; Mitrenga, D; Scheef, W; Schnitker, J; Voigtmann, R, 1979) |
| "Mesna is a sulfhydryl compound that reacts with the metabolites of cyclophosphamide that are excreted in the urine and may produce bladder wall irritation." | 1.27 | Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. ( Luce, JK; Simons, JA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (87.50) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bryant, BM | 1 |
| Jarman, M | 1 |
| Ford, HT | 1 |
| Smith, IE | 1 |
| Burkert, H | 3 |
| Hows, JM | 1 |
| Mehta, A | 1 |
| Ward, L | 1 |
| Woods, K | 1 |
| Perez, R | 1 |
| Gordon, MY | 1 |
| Gordon-Smith, EC | 1 |
| Czownicki, Z | 1 |
| Utracka-Hutka, B | 1 |
| Schnitker, J | 3 |
| Scheef, W | 1 |
| Klein, HO | 1 |
| Brock, N | 2 |
| Günther, U | 1 |
| Hoefer-Janker, H | 1 |
| Mitrenga, D | 1 |
| Voigtmann, R | 1 |
| Fichtner, E | 1 |
| Marti, C | 1 |
| Steiner, R | 1 |
| Viollier, AF | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Williams, SD | 1 |
| Munshi, N | 1 |
| Einhorn, LH | 1 |
| Loehrer, PJ | 1 |
| Antman, KH | 1 |
| Ryan, L | 1 |
| Elias, A | 1 |
| Sherman, D | 1 |
| Grier, HE | 1 |
| Andriole, GL | 1 |
| Sandlund, JT | 1 |
| Miser, JS | 1 |
| Arasi, V | 1 |
| Linehan, M | 1 |
| Magrath, IT | 1 |
| Pratt, CB | 1 |
| Goren, MP | 1 |
| Case, DC | 1 |
| Anderson, J | 1 |
| Ervin, TJ | 1 |
| Gottlieb, A | 1 |
| Li, GC | 1 |
| Li, JQ | 1 |
| Guan, ZZ | 1 |
| He, YJ | 1 |
| Luce, JK | 1 |
| Simons, JA | 1 |
7 trials available for mercaptoethanol and Hematuria
| Article | Year |
|---|---|
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
Topics: Acrolein; Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Female; Hematuria; Hu | 1980 |
Clinical overview of mesna.
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap | 1983 |
Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Colony-Forming Units Assay; | 1984 |
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol | 1981 |
[Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
Topics: Hematuria; Humans; Mercaptoethanol; Mesna; Phosphoramide Mustards; Urologic Diseases | 1982 |
Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
Topics: Clinical Trials as Topic; Cystitis; Drug Therapy, Combination; Hematuria; Humans; Male; Mercaptoetha | 1979 |
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Human | 1989 |
9 other studies available for mercaptoethanol and Hematuria
| Article | Year |
|---|---|
[Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Topics: Adolescent; Adult; Aged; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Gastrointestinal Dise | 1979 |
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Topics: Adult; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Oste | 1979 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Cyclophosphamide and ifosfamide: role of uroprotective agents.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematuria; Humans; | 1990 |
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag | 1987 |
Ifosfamide/mesna and hematuria.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Hematuri | 1987 |
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Hematologic Diseases; Hematuria; Humans | 1988 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
Topics: Adolescent; Adult; Child; Cyclophosphamide; Cystitis; Cystoscopy; Female; Hematuria; Humans; Male; M | 1988 |